Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | 10% owner | September 10, 2021 | September 13, 2021 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | 10% owner | September 19, 2023 | September 19, 2023 |
| TULARIK INCTLRK · Entity 14141 | 10% owner | November 14, 2003 | November 17, 2003 |
| Unilife CorpUNIS · Entity 12414 | 10% owner | February 22, 2016 | March 04, 2016 |
| Vigil Neuroscience, Inc.VIGL · Entity 11675 | 10% owner | January 11, 2022 | January 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date September 10, 2021 · Filed September 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 18,943,802 |
Reported balance
After 2021-09-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-09-10 · Purchase · Acquired 165,529 · Balance 18,943,802 F1: This transaction was made pursuant to that Share Purchase Agreement, dated as of September 24, 2020, as amended, by and between the Reporting Person and the Issuer. F2: The price reported is the volume weighted average price on the NASDAQ Stock Market LLC of one American Depositary Share ("ADS") of the Issuer for the ninety calendar days preceding August 31, 2021. F3: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 246,269,426 Ordinary Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to that Share Purchase Agreement, dated as of September 24, 2020, as amended, by and between the Reporting Person and the Issuer.
F2: The price reported is the volume weighted average price on the NASDAQ Stock Market LLC of one American Depositary Share ("ADS") of the Issuer for the ninety calendar days preceding August 31, 2021.
F3: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 246,269,426 Ordinary Shares.
Neumora Therapeutics, Inc.
Report date September 19, 2023 · Filed September 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,368,653 |
Ending reported balance
After 2023-09-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-19 · Conversion · Acquired 33,603,948 · Balance 33,603,948 F1: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. Row 2 · 2023-09-19 · Purchase · Acquired 1,764,705 · Balance 35,368,653 |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-19 · Conversion · Disposed 32,754,291 · Balance 0 F1: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-19 · Conversion · Disposed 849,657 · Balance 0 F1: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
TULARIK INC
Report date November 14, 2003 · Filed November 17, 2003
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,952,885 |
Reported balance
After 2003-11-14 transaction · row 1
1 source rowRow 1 · 2003-11-14 · Purchase · Acquired 1,452,885 · Balance 13,952,885 |
Unilife Corp
Report date February 22, 2016 · Filed March 04, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 6% Senior Secured Convertible Note due 2023SEC Table II · derivative / convertible security · Expires 2023-02-22 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2016-02-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F2: The 6% Senior Secured Convertible Note due 2023 is convertible into shares of the Issuer's Common Stock at any time prior to February 22, 2023, at a price per share that is 90% of the volume weighted average price of such shares during the twenty (20) trading days preceding the applicable conversion date, subject to a floor price of $1.25 per share (the "Conversion Rate Floor Price"). The Conversion Rate Floor Price is subject to customary adjustments for certain capital events. F1: Includes shares issuable upon the conversion of interest accruable under the 6% Senior Secured Convertible Note due 2023 through maturity and payable through the addition of the amount of such interest to the then outstanding principal amount. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares issuable upon the conversion of interest accruable under the 6% Senior Secured Convertible Note due 2023 through maturity and payable through the addition of the amount of such interest to the then outstanding principal amount.
F2: The 6% Senior Secured Convertible Note due 2023 is convertible into shares of the Issuer's Common Stock at any time prior to February 22, 2023, at a price per share that is 90% of the volume weighted average price of such shares during the twenty (20) trading days preceding the applicable conversion date, subject to a floor price of $1.25 per share (the "Conversion Rate Floor Price"). The Conversion Rate Floor Price is subject to customary adjustments for certain capital events.
Vigil Neuroscience, Inc.
Report date January 11, 2022 · Filed January 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,206,281 |
Reported balance
After 2022-01-11 transaction · row 1
1 source rowRow 1 · 2022-01-11 · Conversion · Acquired 3,206,281 · Balance 3,206,281 F1: These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-11 · Conversion · Disposed 3,206,281 · Balance 0 F1: These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Epizyme, Inc.
Report date June 05, 2013 · Filed June 05, 2013
Jointly reported with Amgen Ventures LLC
Section 16 reporting ended · disclosed 2013-06-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 334,126 |
Last balance in matching sequence
After 2013-06-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2013-06-05 · Conversion · Acquired 317,460 · Balance 317,460 F1: Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F2: These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares. Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. F3: Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock. Row 2 · 2013-06-05 · Purchase · Acquired 16,666 · Balance 334,126 F2: These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares. Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. F3: Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2013-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2013-06-05 · Conversion · Disposed 952,381 · Balance 0 F1: Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F2: These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares. Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. F3: Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date.
F2: These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares. Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
F3: Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock.
Kezar Life Sciences, Inc.
Report date June 25, 2018 · Filed June 26, 2018
Jointly reported with Onyx Therapeutics, Inc.
Section 16 reporting ended · disclosed 2018-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,121,384 |
Reported balance
After 2018-06-25 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-06-25 · Conversion · Acquired 1,121,384 · Balance 1,121,384 F1: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock. F2: These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx. F3: Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-25 · Conversion · Disposed 1,121,384 · Balance 0 F1: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock. F2: These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx. F3: Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock.
F2: These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx.
F3: Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock.
MICROMET, INC.
Report date March 06, 2012 · Filed March 08, 2012
Jointly reported with Armstrong Acquisition Corp.
Section 16 reporting ended · disclosed 2012-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Armstrong Acquisition Corp. | 84,684,189 |
Reported balance
After 2012-03-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2012-03-06 · Purchase · Acquired 2,170,710 · Balance 84,684,189 F1: On March 2, 2012, Armstrong Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"), commenced a subsequent offering period of its tender offer (the "Offer") to acquire all of the outstanding shares of common stock, par value $0.00004 per share (together with the associated preferred share purchase rights, the "Shares") of Micromet, Inc. ("Micromet") at a purchase price of $11.00 per Share in cash (the "Offer Price"). The subsequent offering period expired at 12:00 midnight, New York City time, at the end of March 6, 2012. F2: Based on the information provided to Amgen by the depositary for the Offer, on March 6, 2012, approximately 1,542,600 Shares subject to guaranteed delivery procedures in the initial offering period, as described in the Offer to Purchase, dated February 2, 2012 (the "Offer to Purchase"), had been validly tendered and accepted for payment and approximately 628,110 Shares had been validly tendered and accepted for payment in the subsequent offering period. |
| Common StockSEC Table I · non-derivative | IndirectBy Armstrong Acquisition Corp. | 100,635,409 |
Reported balance
After 2012-03-07 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2012-03-07 · Purchase · Acquired 15,951,220 · Balance 100,635,409 F3: On March 7, 2012, Purchaser exercised its option (the "Top-Up Option") to purchase, at the Offer Price, 15,951,220 Shares (the "Top-Up Shares") from Micromet. The Top-Up Shares, when added to the number of Shares owned by the Purchaser immediately prior to the exercise of the Top-Up Option, resulted in Purchaser owning one Share more than 90% of the Shares of Micromet then outstanding. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2012-03-07 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2012-03-07 · Purchase · Acquired 11,181,711 · Balance 0 F4: On March 7, 2012, following the exercise of the Top-Up Option, Purchaser merged with and into Micromet (the "Merger") under the short-form merger provisions of the General Corporation Law of the State of Delaware, with Micromet continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Amgen. At the effective time of the Merger, each Share issued and outstanding immediately prior to the effective time ceased to be issued and outstanding and (other than Shares then owned by Amgen, Micromet or any of their wholly-owned subsidiaries and Shares held by any stockholders who properly demanded appraisal in connection with the Merger) was converted into the right to receive the Offer Price, without interest, less any applicable withholding taxes. At the effective time of the Merger, all outstanding Shares were cancelled and retired and ceased to exist. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 2, 2012, Armstrong Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"), commenced a subsequent offering period of its tender offer (the "Offer") to acquire all of the outstanding shares of common stock, par value $0.00004 per share (together with the associated preferred share purchase rights, the "Shares") of Micromet, Inc. ("Micromet") at a purchase price of $11.00 per Share in cash (the "Offer Price"). The subsequent offering period expired at 12:00 midnight, New York City time, at the end of March 6, 2012.
F2: Based on the information provided to Amgen by the depositary for the Offer, on March 6, 2012, approximately 1,542,600 Shares subject to guaranteed delivery procedures in the initial offering period, as described in the Offer to Purchase, dated February 2, 2012 (the "Offer to Purchase"), had been validly tendered and accepted for payment and approximately 628,110 Shares had been validly tendered and accepted for payment in the subsequent offering period.
F3: On March 7, 2012, Purchaser exercised its option (the "Top-Up Option") to purchase, at the Offer Price, 15,951,220 Shares (the "Top-Up Shares") from Micromet. The Top-Up Shares, when added to the number of Shares owned by the Purchaser immediately prior to the exercise of the Top-Up Option, resulted in Purchaser owning one Share more than 90% of the Shares of Micromet then outstanding.
F4: On March 7, 2012, following the exercise of the Top-Up Option, Purchaser merged with and into Micromet (the "Merger") under the short-form merger provisions of the General Corporation Law of the State of Delaware, with Micromet continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Amgen. At the effective time of the Merger, each Share issued and outstanding immediately prior to the effective time ceased to be issued and outstanding and (other than Shares then owned by Amgen, Micromet or any of their wholly-owned subsidiaries and Shares held by any stockholders who properly demanded appraisal in connection with the Merger) was converted into the right to receive the Offer Price, without interest, less any applicable withholding taxes. At the effective time of the Merger, all outstanding Shares were cancelled and retired and ceased to exist.
TETRALOGIC PHARMACEUTICALS Corp
Report date December 17, 2013 · Filed December 18, 2013
Jointly reported with Amgen Ventures LLC
Section 16 reporting ended · disclosed 2013-12-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 448,767 |
Reported balance
After 2013-12-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2013-12-17 · Conversion · Acquired 448,767 · Balance 448,767 F2: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. |
| Common StockSEC Table I · non-derivative | IndirectBy Ventures | 541,399 |
Last balance in matching sequence
After 2013-12-17 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2013-12-17 · Conversion · Acquired 268,116 · Balance 268,116 F2: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Row 3 · 2013-12-17 · Other · Acquired 1,141 · Balance 269,257 F3: In accordance with the terms of the Warrant to Purchase Equity Securities, the warrant was net exercised and based on a fair market value of $7.00 per share, a net of 1,141 shares were acquired by Ventures. F2: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Row 4 · 2013-12-17 · Purchase · Acquired 272,142 · Balance 541,399 F1: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
| Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $7.00 | Direct | 0 |
Reported balance
After 2013-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2013-12-17 · Conversion · Disposed Not disclosed · Balance 0 F2: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Ventures | 0 |
Reported balance
After 2013-12-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2013-12-17 · Conversion · Disposed 108,932 · Balance 0 F2: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Ventures | 0 |
Reported balance
After 2013-12-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2013-12-17 · Conversion · Disposed 117,361 · Balance 0 F2: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
| Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $7.00 | IndirectBy Ventures | 0 |
Reported balance
After 2013-12-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2013-12-17 · Conversion · Disposed Not disclosed · Balance 0 F2: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
| Series C Convertible Preferred Stock Warrants (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 | IndirectBy Ventures | 0 |
Reported balance
After 2013-12-17 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2013-12-17 · Other · Disposed 13,355 · Balance 0 F2: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
F2: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock.
F3: In accordance with the terms of the Warrant to Purchase Equity Securities, the warrant was net exercised and based on a fair market value of $7.00 per share, a net of 1,141 shares were acquired by Ventures.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2023 Filed Sep 19, 2023 23:52 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries B Preferred Stock · Derivative | 849,657 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000289 · form4.xml · derivative · entry 4 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 849,657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 23:52 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-2 Preferred Stock · Derivative | 32,754,291 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000289 · form4.xml · derivative · entry 3 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,754,291 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 23:52 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 1,764,705 | $17.00 | $29,999,985.00 |
DisclosureSEC source: 0001610717-23-000289 · form4.xml · nonDerivative · entry 2 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,368,653 Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 23:52 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 33,603,948 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-23-000289 · form4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,603,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 02:33 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | ConversionSeries A Preferred Stock · Derivative | 3,206,281 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001666 · doc4.xml · derivative · entry 2 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,206,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering F1 · price: These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering F1 · derivative.exercise_date: These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering F1 · derivative.expiration_date: These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 02:33 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | ConversionCommon Stock | 3,206,281 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001666 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,206,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 23:27 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | PurchaseAmerican Depositary Shares | 165,529 | $302.06 | $49,999,938.03 |
DisclosureSEC source: 0000899243-21-035731 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,943,802 F1 · shares: This transaction was made pursuant to that Share Purchase Agreement, dated as of September 24, 2020, as amended, by and between the Reporting Person and the Issuer. F2 · price: The price reported is the volume weighted average price on the NASDAQ Stock Market LLC of one American Depositary Share ("ADS") of the Issuer for the ninety calendar days preceding August 31, 2021. F3 · balance_after: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 246,269,426 Ordinary Shares. Read SEC document |
| December 18, 2020 Filed Dec 19, 2020 02:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 25,762 | $260.95 | $6,722,503.73 |
DisclosureSEC source: 0000899243-20-034573 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,778,273 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F2 · price: The price reported is an average price. These American Depositary Shares ("ADSs") were purchased at prices ranging from $256.72 to $264.92 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. F3 · balance_after: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 244,117,549 Ordinary Shares. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 02:18 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 74,624 | $260.54 | $19,442,507.11 |
DisclosureSEC source: 0000899243-20-034372 · doc4.xml · nonDerivative · entry 3 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,752,511 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F4 · price: The price reported is an average price. These ADSs were purchased at prices ranging from $254.135 to $265.00 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. F5 · balance_after: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 243,782,643 Ordinary Shares. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 02:18 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 85,573 | $248.26 | $21,244,455.67 |
DisclosureSEC source: 0000899243-20-034372 · doc4.xml · nonDerivative · entry 2 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,677,887 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F3 · price: The price reported is an average price. These ADSs were purchased at prices ranging from $241.29 to $250.17 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 02:18 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 67,941 | $239.31 | $16,258,722.92 |
DisclosureSEC source: 0000899243-20-034372 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,592,314 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F2 · price: The price reported is an average price. These American Depositary Shares ("ADSs") were purchased at prices ranging from $232.86 to $241.845 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| August 25, 2020 Filed Aug 25, 2020 21:55 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 59,390 | $248.49 | $14,757,577.60 |
DisclosureSEC source: 0000899243-20-023386 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,524,373 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F2 · price: The price reported is an average price. These American Depositary Shares ("ADSs") were purchased at prices ranging from $238.13 to $254.57 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. F3 · balance_after: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 240,816,849 Ordinary Shares. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 21:47 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 59,390 | $239.10 | $14,199,905.50 |
DisclosureSEC source: 0000899243-20-023319 · doc4.xml · nonDerivative · entry 2 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,464,983 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F3 · price: The price reported is an average price. These ADSs were purchased at prices ranging from $235.15 to $242.535 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. F4 · balance_after: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 240,044,779 Ordinary Shares. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 21:47 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 64,176 | $230.18 | $14,772,012.43 |
DisclosureSEC source: 0000899243-20-023319 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,405,593 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F2 · price: The price reported is an average price. These American Depositary Shares ("ADSs") were purchased at prices ranging from $237.33 to $243.11 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| August 20, 2020 Filed Aug 20, 2020 23:28 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 64,176 | $234.99 | $15,080,981.36 |
DisclosureSEC source: 0000899243-20-023107 · doc4.xml · nonDerivative · entry 3 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,341,417 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F4 · price: The price reported is an average price. These ADSs were purchased at prices ranging from $229.60 to $237.93 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. F5 · balance_after: As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 238,438,421 Ordinary Shares. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 23:28 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 64,176 | $234.88 | $15,073,453.52 |
DisclosureSEC source: 0000899243-20-023107 · doc4.xml · nonDerivative · entry 2 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,277,241 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F3 · price: The price reported is an average price. These ADSs were purchased at prices ranging from $231.33 to $237.16 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 23:28 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 40,000 | $230.18 | $9,207,188.00 |
DisclosureSEC source: 0000899243-20-023107 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,213,065 F1 · shares: This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F2 · price: The price reported is an average price. These American Depositary Shares ("ADSs") were purchased at prices ranging from $223.35 to $235.21 per ADS. Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 21:18 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 29,614,832 | $14.23 | $421,442,751.23 |
DisclosureSEC source: 0000899243-20-019383 · doc4.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,249,845 F1 · balance_after: Includes 206,635,013 securities represented by American Depositary Shares, each of which represents 13 Ordinary Shares of the Issuer. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 01:14 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 1,121,384 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018026 · doc4.xml · derivative · entry 2 Onyx Therapeutics, Inc. · CIK 0001744260 · 10% owner AMGEN INC · CIK 0000318154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,121,384 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock. F1 · derivative.exercise_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock. F1 · derivative.expiration_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock. F2 · ownership.direct: These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx. F3 · ownership.direct: Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 01:14 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionCommon Stock | 1,121,384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018026 · doc4.xml · nonDerivative · entry 1 Onyx Therapeutics, Inc. · CIK 0001744260 · 10% owner AMGEN INC · CIK 0000318154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,121,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock. F2 · ownership.direct: These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx. F3 · ownership.direct: Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock. Read SEC document |
| December 17, 2013 Filed Dec 18, 2013 23:09 UTC | TETRALOGIC PHARMACEUTICALS Corp TLOG · Entity 12646 | OtherSeries C Convertible Preferred Stock Warrants (Right To Buy) · Derivative | 13,355 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001181431-13-063433 · rrd395732.xml · derivative · entry 9 AMGEN INC · CIK 0000318154 · 10% owner Amgen Ventures LLC · CIK 0001576997 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Ventures Disclosed balance after: 0 Underlying: Common Stock · 13,355 shares Expires not disclosed F2 · derivative.exercise_price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.exercise_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.expiration_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1 · ownership.nature: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| December 17, 2013 Filed Dec 18, 2013 23:09 UTC | TETRALOGIC PHARMACEUTICALS Corp TLOG · Entity 12646 | ConversionConvertible Notes · Derivative | Not disclosed | $0.00 Strike: $7.00 | $279,103.00 |
DisclosureSEC source: 0001181431-13-063433 · rrd395732.xml · derivative · entry 8 AMGEN INC · CIK 0000318154 · 10% owner Amgen Ventures LLC · CIK 0001576997 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Ventures Disclosed balance after: 0 Underlying: Common Stock · 41,823 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.exercise_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.expiration_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1 · ownership.nature: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| December 17, 2013 Filed Dec 18, 2013 23:09 UTC | TETRALOGIC PHARMACEUTICALS Corp TLOG · Entity 12646 | ConversionSeries C Convertible Preferred Stock · Derivative | 117,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-13-063433 · rrd395732.xml · derivative · entry 7 AMGEN INC · CIK 0000318154 · 10% owner Amgen Ventures LLC · CIK 0001576997 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Ventures Disclosed balance after: 0 Underlying: Common Stock · 117,361 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.exercise_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.expiration_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1 · ownership.nature: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| December 17, 2013 Filed Dec 18, 2013 23:09 UTC | TETRALOGIC PHARMACEUTICALS Corp TLOG · Entity 12646 | ConversionSeries B Convertible Preferred Stock · Derivative | 108,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-13-063433 · rrd395732.xml · derivative · entry 6 AMGEN INC · CIK 0000318154 · 10% owner Amgen Ventures LLC · CIK 0001576997 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Ventures Disclosed balance after: 0 Underlying: Common Stock · 108,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.exercise_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.expiration_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1 · ownership.nature: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| December 17, 2013 Filed Dec 18, 2013 23:09 UTC | TETRALOGIC PHARMACEUTICALS Corp TLOG · Entity 12646 | ConversionConvertible Notes · Derivative | Not disclosed | $0.00 Strike: $7.00 | $3,000,000.00 |
DisclosureSEC source: 0001181431-13-063433 · rrd395732.xml · derivative · entry 5 AMGEN INC · CIK 0000318154 · 10% owner Amgen Ventures LLC · CIK 0001576997 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 448,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.exercise_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F2 · derivative.expiration_date: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. Read SEC document |
| December 17, 2013 Filed Dec 18, 2013 23:09 UTC | TETRALOGIC PHARMACEUTICALS Corp TLOG · Entity 12646 | PurchaseCommon Stock | 272,142 | $7.00 | $1,904,994.00 |
DisclosureSEC source: 0001181431-13-063433 · rrd395732.xml · nonDerivative · entry 4 AMGEN INC · CIK 0000318154 · 10% owner Amgen Ventures LLC · CIK 0001576997 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Ventures Disclosed balance after: 541,399 F1 · ownership.nature: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| December 17, 2013 Filed Dec 18, 2013 23:09 UTC | TETRALOGIC PHARMACEUTICALS Corp TLOG · Entity 12646 | OtherCommon Stock | 1,141 | $6.40 | $7,304.91 |
DisclosureSEC source: 0001181431-13-063433 · rrd395732.xml · nonDerivative · entry 3 AMGEN INC · CIK 0000318154 · 10% owner Amgen Ventures LLC · CIK 0001576997 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Ventures Disclosed balance after: 269,257 F3 · shares: In accordance with the terms of the Warrant to Purchase Equity Securities, the warrant was net exercised and based on a fair market value of $7.00 per share, a net of 1,141 shares were acquired by Ventures. F2 · price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1 · ownership.nature: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| December 17, 2013 Filed Dec 18, 2013 23:09 UTC | TETRALOGIC PHARMACEUTICALS Corp TLOG · Entity 12646 | ConversionCommon Stock | 268,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-13-063433 · rrd395732.xml · nonDerivative · entry 2 AMGEN INC · CIK 0000318154 · 10% owner Amgen Ventures LLC · CIK 0001576997 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Ventures Disclosed balance after: 268,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. F1 · ownership.nature: Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| December 17, 2013 Filed Dec 18, 2013 23:09 UTC | TETRALOGIC PHARMACEUTICALS Corp TLOG · Entity 12646 | ConversionCommon Stock | 448,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-13-063433 · rrd395732.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner Amgen Ventures LLC · CIK 0001576997 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock. Read SEC document |
| June 05, 2013 Filed Jun 5, 2013 20:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | ConversionSeries B Preferred Stock · Derivative | 952,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-13-032856 · rrd380749.xml · derivative · entry 3 Amgen Ventures LLC · CIK 0001576997 · 10% owner AMGEN INC · CIK 0000318154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 317,460 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F2 · ownership.direct: These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares. Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. F3 · ownership.direct: Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock. Read SEC document |
| June 05, 2013 Filed Jun 5, 2013 20:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | PurchaseCommon Stock | 16,666 | $15.00 | $249,990.00 |
DisclosureSEC source: 0001181431-13-032856 · rrd380749.xml · nonDerivative · entry 2 Amgen Ventures LLC · CIK 0001576997 · 10% owner AMGEN INC · CIK 0000318154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,126 F2 · ownership.direct: These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares. Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. F3 · ownership.direct: Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock. Read SEC document |
| June 05, 2013 Filed Jun 5, 2013 20:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | ConversionCommon Stock | 317,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001181431-13-032856 · rrd380749.xml · nonDerivative · entry 1 Amgen Ventures LLC · CIK 0001576997 · 10% owner AMGEN INC · CIK 0000318154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date. F2 · ownership.direct: These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares. Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. F3 · ownership.direct: Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock. Read SEC document |
| March 07, 2012 Filed Mar 8, 2012 01:41 UTC | MICROMET, INC. MITI · Entity 12926 | PurchaseCommon Stock | 11,181,711 | $11.00 | $122,998,821.00 |
DisclosureSEC source: 0001181431-12-015374 · rrd337739.xml · nonDerivative · entry 3 AMGEN INC · CIK 0000318154 · 10% owner Armstrong Acquisition Corp. · CIK 0001543400 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · shares: On March 7, 2012, following the exercise of the Top-Up Option, Purchaser merged with and into Micromet (the "Merger") under the short-form merger provisions of the General Corporation Law of the State of Delaware, with Micromet continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Amgen. At the effective time of the Merger, each Share issued and outstanding immediately prior to the effective time ceased to be issued and outstanding and (other than Shares then owned by Amgen, Micromet or any of their wholly-owned subsidiaries and Shares held by any stockholders who properly demanded appraisal in connection with the Merger) was converted into the right to receive the Offer Price, without interest, less any applicable withholding taxes. At the effective time of the Merger, all outstanding Shares were cancelled and retired and ceased to exist. F4 · balance_after: On March 7, 2012, following the exercise of the Top-Up Option, Purchaser merged with and into Micromet (the "Merger") under the short-form merger provisions of the General Corporation Law of the State of Delaware, with Micromet continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Amgen. At the effective time of the Merger, each Share issued and outstanding immediately prior to the effective time ceased to be issued and outstanding and (other than Shares then owned by Amgen, Micromet or any of their wholly-owned subsidiaries and Shares held by any stockholders who properly demanded appraisal in connection with the Merger) was converted into the right to receive the Offer Price, without interest, less any applicable withholding taxes. At the effective time of the Merger, all outstanding Shares were cancelled and retired and ceased to exist. Read SEC document |
| March 07, 2012 Filed Mar 8, 2012 01:41 UTC | MICROMET, INC. MITI · Entity 12926 | PurchaseCommon Stock | 15,951,220 | $11.00 | $175,463,420.00 |
DisclosureSEC source: 0001181431-12-015374 · rrd337739.xml · nonDerivative · entry 2 AMGEN INC · CIK 0000318154 · 10% owner Armstrong Acquisition Corp. · CIK 0001543400 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Armstrong Acquisition Corp. Disclosed balance after: 100,635,409 F3 · shares: On March 7, 2012, Purchaser exercised its option (the "Top-Up Option") to purchase, at the Offer Price, 15,951,220 Shares (the "Top-Up Shares") from Micromet. The Top-Up Shares, when added to the number of Shares owned by the Purchaser immediately prior to the exercise of the Top-Up Option, resulted in Purchaser owning one Share more than 90% of the Shares of Micromet then outstanding. Read SEC document |
| March 06, 2012 Filed Mar 8, 2012 01:41 UTC | MICROMET, INC. MITI · Entity 12926 | PurchaseCommon Stock | 2,170,710 | $11.00 | $23,877,810.00 |
DisclosureSEC source: 0001181431-12-015374 · rrd337739.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner Armstrong Acquisition Corp. · CIK 0001543400 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Armstrong Acquisition Corp. Disclosed balance after: 84,684,189 F1 · shares: On March 2, 2012, Armstrong Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"), commenced a subsequent offering period of its tender offer (the "Offer") to acquire all of the outstanding shares of common stock, par value $0.00004 per share (together with the associated preferred share purchase rights, the "Shares") of Micromet, Inc. ("Micromet") at a purchase price of $11.00 per Share in cash (the "Offer Price"). The subsequent offering period expired at 12:00 midnight, New York City time, at the end of March 6, 2012. F2 · shares: Based on the information provided to Amgen by the depositary for the Offer, on March 6, 2012, approximately 1,542,600 Shares subject to guaranteed delivery procedures in the initial offering period, as described in the Offer to Purchase, dated February 2, 2012 (the "Offer to Purchase"), had been validly tendered and accepted for payment and approximately 628,110 Shares had been validly tendered and accepted for payment in the subsequent offering period. Read SEC document |
| March 05, 2012 Filed Mar 7, 2012 00:53 UTC | MICROMET, INC. MITI · Entity 12926 | PurchaseCommon Stock | 2,035,994 | $11.00 | $22,395,934.00 |
DisclosureSEC source: 0001181431-12-014968 · rrd337354.xml · nonDerivative · entry 2 AMGEN INC · CIK 0000318154 · 10% owner Armstrong Acquisition Corp. · CIK 0001543400 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Armstrong Acquisition Corp. Disclosed balance after: 82,513,479 F2 · shares: Following the Expiration Date, the Purchaser commenced a subsequent offering period (the "Subsequent Offer") to acquire all of the remaining untendered Shares of Micromet. The Subsequent Offer is scheduled to expire at 12:00 midnight, New York City time, at the end of March 6, 2012. Shares validly tendered during this Subsequent Offer are accepted immediately for payment and tendering stockholders are paid the Offer Price, upon the same terms and subject to the same conditions as the Initial Offer, as set forth in the Offer to Purchase and the related Letter of Transmittal included as exhibits to the Tender Offer Statement on Schedule TO-T filed by Purchaser and Amgen with the Securities and Exchange Commission on February 2, 2012, except that Shares tendered during the Subsequent Offer may not be withdrawn. F3 · shares: Based on the information provided to Amgen by the Depositary on March 5, 2012, approximately 349,177 Shares subject to guaranteed delivery procedures in the Initial Offer, as described in the Offer to Purchase, had been validly tendered and accepted for payment and approximately 1,686,817 Shares had been validly tendered and accepted for payment in the Subsequent Offer. Read SEC document |
| March 02, 2012 Filed Mar 7, 2012 00:53 UTC | MICROMET, INC. MITI · Entity 12926 | PurchaseCommon Stock | 452,388 | $11.00 | $4,976,268.00 |
DisclosureSEC source: 0001181431-12-014968 · rrd337354.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner Armstrong Acquisition Corp. · CIK 0001543400 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Armstrong Acquisition Corp. Disclosed balance after: 80,477,485 F1 · shares: The initial tender offer (the "Initial Offer") commenced by Armstrong Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"), to acquire all of the outstanding shares of common stock, par value $0.00004 per share (together with the associated preferred share purchase rights, the "Shares") of Micromet, Inc. ("Micromet") at a purchase price of $11.00 per Share in cash (the "Offer Price") expired at 12:00 midnight, New York City time, at the end of Thursday, March 1, 2012 (the "Expiration Date"). Based on the information provided to Amgen by the depositary for the tender offers (the "Depositary") on March 2, 2012, approximately 452,388 Shares subject to guaranteed delivery procedures in the Initial Offer, as described in the Offer to Purchase, dated February 2, 2012 (the "Offer to Purchase"), had been validly tendered and accepted for payment. Read SEC document |
| November 14, 2003 Filed Nov 17, 2003 17:29 UTC | TULARIK INC TLRK · Entity 14141 | PurchaseCommon Stock | 1,452,885 | $11.90 | $17,289,331.50 |
DisclosureSEC source: 0001181431-03-031206 · rrd22904.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,952,885 Read SEC document |
| July 08, 2003 Filed Jul 8, 2003 22:41 UTC | TULARIK INC TLRK · Entity 14141 | PurchaseCommon Stock | 3,000,000 | $7.50 | $22,500,000.00 |
DisclosureSEC source: 0001181431-03-013398 · rrd12642.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500,000 Read SEC document |
| June 27, 2003 Filed Jul 1, 2003 20:42 UTC | TULARIK INC TLRK · Entity 14141 | PurchaseCommon Stock | 3,500,000 | $10.00 | $35,000,000.00 |
DisclosureSEC source: 0001181431-03-012412 · rrd11544.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500,000 Read SEC document |
| Date not disclosed Filed Jun 2, 2003 19:52 UTC | TULARIK INC TLRK · Entity 14141 | OtherCommon Stock | 6,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001181431-03-009586 · rrd9866.xml · nonDerivative · entry 1 AMGEN INC · CIK 0000318154 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.